1. Home
  2. NEUP vs GXAI Comparison

NEUP vs GXAI Comparison

Compare NEUP & GXAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NEUP
  • GXAI
  • Stock Information
  • Founded
  • NEUP 1996
  • GXAI 2021
  • Country
  • NEUP United States
  • GXAI United States
  • Employees
  • NEUP N/A
  • GXAI N/A
  • Industry
  • NEUP
  • GXAI
  • Sector
  • NEUP
  • GXAI
  • Exchange
  • NEUP Nasdaq
  • GXAI Nasdaq
  • Market Cap
  • NEUP 12.7M
  • GXAI 13.0M
  • IPO Year
  • NEUP N/A
  • GXAI 2023
  • Fundamental
  • Price
  • NEUP $17.24
  • GXAI $1.96
  • Analyst Decision
  • NEUP Strong Buy
  • GXAI
  • Analyst Count
  • NEUP 2
  • GXAI 0
  • Target Price
  • NEUP $28.00
  • GXAI N/A
  • AVG Volume (30 Days)
  • NEUP 95.7K
  • GXAI 424.6K
  • Earning Date
  • NEUP 11-15-2025
  • GXAI 11-13-2025
  • Dividend Yield
  • NEUP N/A
  • GXAI N/A
  • EPS Growth
  • NEUP N/A
  • GXAI N/A
  • EPS
  • NEUP N/A
  • GXAI N/A
  • Revenue
  • NEUP $15,649,448.00
  • GXAI $198,711.00
  • Revenue This Year
  • NEUP N/A
  • GXAI N/A
  • Revenue Next Year
  • NEUP N/A
  • GXAI N/A
  • P/E Ratio
  • NEUP N/A
  • GXAI N/A
  • Revenue Growth
  • NEUP N/A
  • GXAI 72158.55
  • 52 Week Low
  • NEUP $2.90
  • GXAI $1.00
  • 52 Week High
  • NEUP $126.00
  • GXAI $7.50
  • Technical
  • Relative Strength Index (RSI)
  • NEUP 60.56
  • GXAI 56.60
  • Support Level
  • NEUP $14.64
  • GXAI $1.80
  • Resistance Level
  • NEUP $19.21
  • GXAI $2.18
  • Average True Range (ATR)
  • NEUP 2.14
  • GXAI 0.16
  • MACD
  • NEUP -0.03
  • GXAI 0.02
  • Stochastic Oscillator
  • NEUP 59.46
  • GXAI 61.11

About NEUP Neuphoria Therapeutics Inc. Common Stock

Neuphoria Therapeutics Inc is a clinical stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder.

About GXAI Gaxos.ai Inc.

Gaxos.AI Inc is revolutionizing the way humans interact with artificial intelligence. The company offers applications related to mental and physical well-being, coaching, and gaming. The group is committed to tackling contemporary challenges such as how to live healthier and how to live longer. In addition to offering human-centered solutions, the company uses empathetic and AI technologies.

Share on Social Networks: